Medical News

RSS

Regis to kick off Clip for the Cure campaign to raise money, awareness for breast cancer research

In October, Regis Corporation, the global leader in the haircare industry, will kick off its annual Clip for the Cure, a month-long campaign to raise money and awareness for breast cancer research in support of National Breast Cancer Awareness Month. To date, the company's dedicated stylists and clients have raised more than $6.5 million for the cause.

13 Sep 2010

Geron, UCS collaborate to develop hESC-derived chondrocytes for cartilage damage, joint disease treatment

Geron Corporation today announced that the company has entered into a collaboration with University Campus Suffolk (UCS) in the U.K. to develop human embryonic stem cell-derived chondrocytes for the treatment of cartilage damage and joint disease.

13 Sep 2010

SPADnet to develop CMOS image sensors for photon-starved biomedical applications

SPADnet aims to develop a new generation of smart, CMOS-based large area networked image sensors for photon-starved biomedical applications. "Fully Networked, Digital Components for Photon-starved Biomedical Imaging Systems" - is a new collaborative research project funded by the European Union within the Information and Communication Technologies (ICT) Theme of its Seventh Research Framework Programme (FP7).

13 Sep 2010

Positron announces opening of Clinical and Technical Cardiovascular PET Training Institute

Positron Corporation, a molecular imaging company specializing in Nuclear Cardiology and a leader in Cardiac PET, announced today the grand opening of its Clinical and Technical Cardiovascular PET Training Institute in Niagara Falls, NY.

13 Sep 2010

Jennerex reports positive interim data from trial of JX-594 and sorafenib for liver cancer

Jennerex, Inc., a clinical-stage biotherapeutics company focused on the development of first-in-class, targeted oncolytic products for cancer, today reported positive interim data from a pilot trial using JX-594 followed by sorafenib (Nexavar®) to treat liver cancer patients. The data were presented today at the Fourth Annual International Liver Cancer Association Conference in Montreal, Canada.

13 Sep 2010

AB SCIEX, University of Melbourne join to develop drug metabolism studies of biopharmaceuticals

AB SCIEX, a global leader in life science analytical technologies, and the University of Melbourne today announced a joint technology development project to improve drug metabolism studies of biopharmaceuticals.

13 Sep 2010

InterMune's development program for pirfenidone, IPF to be presented at Annual Congress of ERS

InterMune, Inc. today announced that four oral presentations related to the company's development program for pirfenidone and idiopathic pulmonary fibrosis will be presented at the Annual Congress of the European Respiratory Society, to be held September 18-22 in Barcelona, Spain.

13 Sep 2010

Forest files response to FDA Complete Response Letter for roflumilast NDA

Forest Laboratories, Inc. today announced that it has filed a response to the U.S. Food & Drug Administration (FDA) addressing topics raised in the complete response letter regarding the New Drug Application (NDA) for roflumilast. Forest licenses roflumilast from Nycomed, which submitted the original NDA.

13 Sep 2010

Tetraphase Pharmaceuticals presents TP-434 drug candidate clinical data

Tetraphase Pharmaceuticals, Inc., yesterday presented new clinical and preclinical data for its lead drug candidate, TP-434, which demonstrated the novel antibiotic as a once daily intravenous (I.V.) monotherapy capable of treating multidrug-resistant gram-negative pathogens while also having potency and broad spectrum coverage of other serious and multidrug resistant gram-positive pathogens.

13 Sep 2010

Geron signs worldwide, exclusive license agreement with University of Edinburgh

Geron Corporation today announced that it has entered into a worldwide, exclusive license agreement with the University of Edinburgh covering technology that allows the efficient production of chondrocytes (cartilage forming cells) from human pluripotent stem cells.

13 Sep 2010

SpineAlign commences enrollment in European Observational Registry for VerteLift System

SpineAlign Medical, Inc. announced today that it has enrolled its initial patient in the European Observational Registry for the VerteLift System, an observation study to further assess the ability of the VerteLift System to treat the pain and dysfunction associated with osteoporotic vertebral compression fractures (VCF), while providing clinically measurable height restoration based upon previous European experience and analysis.

13 Sep 2010

Pro-Pharmaceuticals engages Numoda Corporation to optimize DAVANAT Phase III clinical trial

Pro-Pharmaceuticals, Inc., the leading developer of therapeutics that target Galectin receptors to treat cancer and fibrosis, today announced that it has engaged the Numoda Corporation, a leading information, process and logistics management company, to oversee the Phase III clinical trial of DAVANAT and 5-FU compared with the standard of care in the treatment of patients with advanced, metastatic colorectal cancer.

13 Sep 2010

Scientists to present preclinical pharmacology data on TRV120027 at Heart Failure Society of America Meeting

Trevena Inc., the leader in the discovery and development of G-protein coupled receptor biased ligands, today announced that its scientists are presenting two posters featuring compelling preclinical pharmacology data on TRV120027 at the 14th Annual Heart Failure Society of America Meeting being held September 12-15, 2010 in San Diego.

13 Sep 2010

Incyte Corporation enters SPA agreement with FDA for INCB18424 inhibitor

Incyte Corporation announced today that it has reached agreement with the U.S. Food and Drug Administration (FDA) regarding a Special Protocol Assessment (SPA) for the design of a pivotal Phase III trial for its JAK1 and JAK2 inhibitor, INCB18424 in patients with polycythemia vera (PV), a blood cancer that belongs to a group of diseases known as myeloproliferative neoplasms (MPNs).

13 Sep 2010

ARIAD commences ponatinib Phase 2 clinical trial in Ph+ ALL and chronic myeloid leukemia

ARIAD Pharmaceuticals, Inc. today announced the initiation of the pivotal Phase 2 clinical trial of its investigational pan-BCR-ABL inhibitor, ponatinib (previously known as AP24534), in patients with resistant or intolerant chronic myeloid leukemia (CML) and Philadelphia positive acute lymphoblastic leukemia (Ph+ ALL).

13 Sep 2010

PDL BioPharma announces conversion rate adjustment for Convertible Senior Notes due 2012

PDL BioPharma, Inc. today announced an adjustment to the conversion rate for its 2.00% Convertible Senior Notes due February 15, 2012 (the 2012 Notes) effective September 16, 2010 in connection with the special dividend to be paid on October 1, 2010 to all stockholders who own shares of PDL on September 15, 2010, the record date.

13 Sep 2010

XenoPort intends to initiate Phase 3 XP19986 trial for multiple sclerosis

XenoPort, Inc. announced today that it plans to move arbaclofen placarbil (AP), also known as XP19986, into Phase 3 development as a potential treatment of spasticity in multiple sclerosis (MS) patients.

13 Sep 2010

Daiichi Sankyo receives marketing approval for Inavir in Japan

Biota Holdings Limited today announced that Daiichi Sankyo has received approval to manufacture and market Inavir® in Japan. Inavir® is Daiichi Sankyo's brand of laninamivir octanoate and also previously known as CS-8958. The approved indication is for the treatment of influenza in adults and children.

13 Sep 2010

First Edition: September 13, 2010

In this morning's news, many in Congress are pushing for repeal of a tax provision in the health law that critics say places a heavy burden on small businesses. Meanwhile, opponents of the overhaul are focused on a Florida court hearing.

13 Sep 2010

Sebelius to discuss Obama Administration's efforts to combat AIDS epidemic in America

On Monday, September 13, U.S. Department of Health and Human Services Secretary Kathleen Sebelius will address approximately 3,000 HIV/AIDS activists and advocates at the United States Conference on AIDS (USCA) in Orlando, Florida, the largest AIDS-related gathering in the country.

13 Sep 2010

Medical News

Regis to kick off Clip for the Cure campaign to raise money, awareness for breast cancer research

Geron, UCS collaborate to develop hESC-derived chondrocytes for cartilage damage, joint disease treatment

SPADnet to develop CMOS image sensors for photon-starved biomedical applications

Positron announces opening of Clinical and Technical Cardiovascular PET Training Institute

Jennerex reports positive interim data from trial of JX-594 and sorafenib for liver cancer

AB SCIEX, University of Melbourne join to develop drug metabolism studies of biopharmaceuticals

InterMune's development program for pirfenidone, IPF to be presented at Annual Congress of ERS

Forest files response to FDA Complete Response Letter for roflumilast NDA

Tetraphase Pharmaceuticals presents TP-434 drug candidate clinical data

Geron signs worldwide, exclusive license agreement with University of Edinburgh

SpineAlign commences enrollment in European Observational Registry for VerteLift System

Pro-Pharmaceuticals engages Numoda Corporation to optimize DAVANAT Phase III clinical trial

Scientists to present preclinical pharmacology data on TRV120027 at Heart Failure Society of America Meeting

Incyte Corporation enters SPA agreement with FDA for INCB18424 inhibitor

ARIAD commences ponatinib Phase 2 clinical trial in Ph+ ALL and chronic myeloid leukemia

PDL BioPharma announces conversion rate adjustment for Convertible Senior Notes due 2012

XenoPort intends to initiate Phase 3 XP19986 trial for multiple sclerosis

Daiichi Sankyo receives marketing approval for Inavir in Japan

First Edition: September 13, 2010

Sebelius to discuss Obama Administration's efforts to combat AIDS epidemic in America

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News